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Background: Based on its pharmacokinetic profile and electrophysiological effects in healthy
horses, sotalol potentially could be used as a long-term PO antiarrhythmic drug in horses.
Objectives: To evaluate the effect of sotalol on heart rate (HR), QT interval, atrial fibrillatory
rate, and success of cardioversion in horses with naturally occurring chronic atrial fibrillation
(AF).
Animals: Twenty-eight horses referred for transvenous electrical cardioversion of AF were treated
with 2 mg/kg sotalol PO q12h for 3 days before cardioversion, and 13 horses underwent the same
protocol without sotalol administration.
Methods: Retrospective study. Before and after sotalol or no treatment, the HR was measured at
rest and during an exercise test. The QT interval and atrial fibrillation cycle length (AFCL) were
measured at rest using tissue Doppler velocity imaging.
Results: In the control group, no significant differences were found between the 2 examinations.
In the sotalol group, the HR at rest and during exercise was significantly lower after sotalol treat-
ment, whereas the QT interval and AFCL measured by tissue Doppler increased significantly.
Cardioversion to sinus rhythm was achieved in 25/28 horses in the sotalol group and all horses in
the control group, but the median number of shocks and energy at cardioversion were significantly
lower in the sotalol group.
Conclusions and Clinical Importance: In horses with AF, sotalol administration results in class III
antiarrhythmic effects and b-blocking activity, with moderate HR reduction during exercise.
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1 | INTRODUCTION
Atrial fibrillation (AF) is a relatively common arrhythmia in horses,
which often presents as so-called “lone AF” without underlying struc-
tural cardiac disease. Pharmacological or transvenous electrical cardio-
version (TVEC) to sinus rhythm is usually recommended in equine
Abbreviations: AERP, atrial effective refractory period; AF, atrial fibrillation;
AFCL, atrial fibrillation cycle length; ERP, effective refractory period; HR,
heart rate; TVEC, transvenous electrical cardioversion.
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athletes because AF limits performance in horses used for intensive ath-
letic work. Even at lower levels of exercise intensity, horses in AF might
exhibit extremely high heart rates (HRs), and collapse has been
described.1 The success rate for both pharmacological cardioversion and
TVEC is very high, but AF recurrence after treatment is common with an
overall rate of recurrence up to 39% at 1 year after cardioversion.2–5
The pathophysiology of AF initiation and perpetuation in horses has not
yet been completely elucidated. Factors that might be associated with
AF recurrence include structural changes to the atrial myocardium, atrial
size and stretch, short atrial effective refractory period (AERP), and
supraventricular ectopic foci.2,6 Long-term antiarrhythmic treatment
could be used to prevent AF recurrence after cardioversion through dif-
ferent mechanisms such as increasing AERP, decreasing supraventricular
ectopy, and decreasing vulnerability to AF initiation. As has been shown
in humans, dogs, and horses, sotalol and other class III antiarrhythmic
drugs lead to lengthening of the repolarization phase of the action
potential by blocking the outward rapid delayed rectifier potassium cur-
rent. This leads to an increase in refractoriness of the tissues. Aside from
reversing the shortening of the monophasic action potential and effec-
tive refractory period (ERP) caused by atrial remodeling during AF,
lengthening of the ERP also decreases the excitability of the cardiac tis-
sues. Therefore, a decrease in ectopic discharges and a decrease in sub-
strate for re-entry are likely. In addition, antiarrhythmic treatment might
be useful to decrease the HR at rest or during exertion in horses in AF.
This rate control therapy possibly could decrease the risk of collapse and
sudden cardiac death. However, long-term PO antiarrhythmic therapy is
rare in horses, and the drugs also might have proarrhythmic effects.
Sotalol can be safely administered with intermediate PO bioavailabil-
ity in horses.7 In human medicine, sotalol is not commonly used for cardi-
oversion of AF, but it is frequently used as an effective drug for
prevention of AF recurrence after cardioversion.8,9 Electrophysiological
effects of sotalol include increased QT interval, decreased HR, and prolon-
gation of the atrioventricular nodal refractory period and PQ interval. In
veterinary medicine, sotalol is the most commonly used long-term treat-
ment for hemodynamically important ventricular arrhythmias in dogs and
cats.10 In healthy horses, sotalol results in prolongation of the QT inter-
val.7,11 However, the use of sotalol has not been described in horses with
cardiac arrhythmias, except in 2 recent reports describing single cases.12,13
Our objectives were to assess the effect of sotalol on HR, QT
interval, atrial fibrillatory rate, and success of cardioversion in horses
with AF. We hypothesized that sotalol administration would result in a
decreased HR at rest and during exercise, a prolonged QT interval and
a decreased atrial fibrillatory rate.
2 | MATERIALS AND METHODS
2.1 | Study design
The study population consisted of 41 horses consecutively admitted for
TVEC treatment of AF at the Department of Large Animal Internal Medi-
cine at the Faculty of Veterinary Medicine, Ghent University. All horses
were examined by an ECG at rest of at least 2 hours duration, an ECG dur-
ing a lunging exercise test14 and echocardiography. After the initial
measurements at admission, the first 28 horses were treated PO with
2 mg/kg sotalol (Sotalol Sandoz, Sandoz, Vilvoorde, Belgium) q12h for 3
days before cardioversion. Echocardiography was repeated just before
TVEC, after 6 doses of sotalol had been administered. The ECG at rest was
repeated after at least 5 doses of sotalol, and the exercise test after at least
4 doses of sotalol. Data always were collected approximately 2–3 hours
after sotalol administration. To determine measurement repeatability, 13
horses underwent the same protocol without sotalol administration. The
TVEC was performed according to procedures described previously.4,15
Shocks were administered under general anesthesia using stepwise
increases of the delivered energy (150, 200, 250, 300, and 360 J) until car-
dioversion. If cardioversion did not occur after the 360 J shock, the cathe-
ters were repositioned andmore high energy shocks were administered.
2.2 | Measurements
The HR at rest was measured from the resting ECG (Televet 100, Engel
Engineering Services GmbH, Heusenstamm, Germany) as an average over
a 30-minute period. The QT interval was measured at rest using the Tele-
vet software calipers (Televet 100, Engel Engineering Services GmbH), as
an average from 10 RR intervals with an instantaneous HR of the preced-
ing RR interval of 35–45 bpm.16 The lunging exercise test consisted of 5
minutes of walk, 10 minutes of trot, 4 minutes of canter, and 1 minute of
gallop. The test was terminated early if the horse showed an excessively
high HR or frequent QRS complexes with an R-on-T morphology. The HR
at walk, trot, and canter was measured over 2 minutes, starting at least 1
minute after the gait transition in order to obtain a relatively stable HR.
The HR during gallop was measured over the entire gallop phase.
The atrial fibrillatory rate was assessed from tissue Doppler veloc-
ity curves of the atrial myocardial walls, as described previously.17,18 In
brief, tissue Doppler images were acquired from the left atrial free wall
in a right parasternal 4-chamber view, from the right atrial dorsal wall
at the level of the tuberculum intervenosum in a right parasternal view
and from the left atrial free wall in a left parasternal long axis view. The
probe frequency was 1.7/3.4 MHz, the image width was 308, image
depth ranged from 22 to 30 cm, and the velocity scale was 116/
216 cm/s (Vivid 7, GE Healthcare, Diegem, Belgium). This resulted in a
frame rate of>180 frames per second. From each view, 10 loops with
a long RR interval (2 s) were stored. Tissue Doppler velocity curves
were acquired off-line by positioning a 5 3 5 mm sample volume in the
atrial myocardial wall (Echopac software version 11.2, GE Healthcare,
Diegem, Belgium). The atrial fibrillation cycle length (AFCL) was meas-
ured from consecutive loops with at least moderate quality, until a min-
imum of 30 AFCL were measured from each view (Figure 1).17,18 These
30 measurements then were averaged to obtain AFCL from each view.
Data were measured by the same experienced observer (B. Broux for
ECG and A. Decloedt for echocardiographic measurements) with the
observer blinded to the identity of the horse and treatment status.
2.3 | Statistics
The number of horses that received sotalol was determined using
power calculation software (G*Power 3.1.9.2, Franz Faul, Universität
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Kiel, Germany) based on a paired comparison with a hypothesized
increase of AFCL of 5 ms and a standard deviation (SD) within the pop-
ulation of 20 ms. Based on this calculation, a sample size of 28 horses
could detect a significant difference with a 2-sided a of 5% and b of
20%. Data were analyzed using dedicated software (SPSS Statistics
version 24, IBM, Armonk, New York). Normality of the data was
checked using visual inspection, the Kolmogorov-Smirnov test, and
Shapiro-Wilk test. HR, QT interval, and AFCL were compared between
groups (sotalol administration or no treatment) and timing (before or
after treatment) using a mixed model with horse as the unit of repeated
measure and treatment and timing as fixed effects. Post hoc Bonferroni
correction was applied for multiple pairwise comparisons. Height, body
weight, age, duration of AF, and cardioversion data were compared
between the sotalol group and the control group using an independent
t test for normally distributed variables or the Mann-Whitney test for
non-normally distributed data. The level of significance was defined as
P< .05.
3 | RESULTS
The sotalol group consisted of 23 Warmbloods, 3 trotters, 1 Paint, and
1 Appaloosa, with a height of 16967 cm (mean, SD), weighing 5656
65 kg, and aged 963 years. The control group consisted of 12 Warm-
bloods and 1 trotter, with a height of 17266 cm, weighing 6056
60 kg, and aged 1063 years. Height, body weight, age, and duration
of AF were not significantly different between groups (P .05). No
adverse effects of sotalol administration were noticed, except for
transient local sweating. During exercise, 4/13 (31%) horses in the
group without treatment showed QRS complexes with an R-on-T mor-
phology during the first test compared to 3/13 horses (23%) during the
second test. In the sotalol group, 5/21 (24%) horses showed QRS com-
plexes with an R-on-T morphology both before and after treatment
(Figure 2). The R-on-T morphology was not consistently present in the
same horses during both exercise tests. In total, 7 horses in the sotalol
group and 5 horses in the control group showed R-on-T morphology
during either the first or the second test. Cardioversion to sinus rhythm
was achieved by the TVEC procedure in 25/28 horses in the sotalol
group and in all horses in the control group. One of the horses that did
not convert underwent a successful second TVEC procedure with ami-
odarone premedication 2 weeks later. Two horses in the sotalol group
showed early recurrence of AF. In 1 horse, recurrence occurred during
anesthesia and the horse was converted to stable sinus rhythm during
the same procedure. In the second horse, recurrence occurred during
recovery. The horse was reanesthetized on the same day and con-
verted to stable sinus rhythm. Amiodarone was administered IV (5 mg/
kg over 30 minutes) to both horses during and immediately after the
second cardioversion. The median number of shocks required for cardi-
oversion to sinus rhythm was 1 (range, 1–4) in the sotalol group, com-
pared to 3 (range, 1–8) in the control group (P5 .016). The median
energy of the shock at cardioversion was 150 J (range, 150–300 J) in
the sotalol group, and 250 J (range, 150–360 J) in the control group
(P5 .023).
The resting HR, QT interval, HRs during exercise, and AFCL before
and after treatment are summarized in Table 1 for the sotalol group
FIGURE 1 Tissue Doppler velocity curve of the left atrial free wall from a left parasternal long axis view with moderate quality (the lowest
quality still included in the study). The biphasic atrial velocity pattern can be distinguished but there is presence of artifacts, indicated by
green arrows. The blue line demonstrates 1 atrial fibrillation cycle length (AFCL) measurement
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and the control group. Within the sotalol group, the resting HR and the
HRs during exercise decreased after treatment compared to before
treatment (Figure 3A), whereas the QT interval and the AFCL measured
in the right atrium and the left atrial free wall from the left parasternal
view increased. In the control group, no significant differences were
found between the 2 examinations (Figure 3B). Compared to the con-
trol group, horses in the sotalol group had lower resting HR, lower HR
during trot and increased QT interval.
4 | DISCUSSION
We describe the effects of sotalol administered PO to horses with AF.
Sotalol treatment resulted in a decrease in HR at rest and during exer-
cise, a prolongation of the QT interval and an increase in AFCL. Signifi-
cantly less energy was required for electrical cardioversion in the
sotalol group, although cardioversion could not be achieved in 3/28
horses, of which 1 horse converted during a second TVEC procedure.
FIGURE 2 High heart rate and QRS complexes with an R-on-T morphology in 1 horse in the sotalol group, after which the exercise test
was terminated early
TABLE 1 Resting HR, QT interval, heart rates during exercise, and AFCL before and after treatment for the sotalol group (n528) and the
control group (n513)
Sotalol group Control group
Mean
ECG 1
SD Mean
ECG 2
SD N
Difference
Mean (95% CI) Mean
ECG 1
SD Mean
ECG 2
SD N
Difference
Mean (95% CI)
HR rest (bpm) 50a 10 41b 6 28 9 (5 to 15) 49a 7 49a,b 7 13 1 (24 to 13)
QT rest (ms) 513a 41 560b 52 28 247 (32 to 62) 521a 23 521a,b 40 13 0 (218 to 118)
HR walk (bpm) 97a 30 77b 20 21 20 (9 to 30) 80a,b 17 79a,b 17 13 1 (213 to 115)
HR trot (bpm) 152a 37 114b 24 21 38 (23 to 52) 140a,b 35 140a 25 13 1 (210 to 19)
HR canter (bpm) 204a 48 165b 34 21 38 (23 to 54) 190a,b 30 183a,b 32 12 7 (21 to 116)
HR gallop (bpm) 246a 29 215b 31 18 32 (14 to 50) 228a,b 30 213b 37 11 18 (1 to 135)
AFCL4CH (ms) 138 13 144 16 28 26 (211 to 0) 145 12 138 18 11 7 (0 to 113)
AFCLRA (ms) 171
a 16 181b 13 28 210 (215 to 25) 179a,b 13 180a,b 16 13 21 (29 to 17)
AFCLLLA (ms) 151
a 13 161b 16 28 210 (215 to 25) 158a,b 11 160a,b 13 13 22 (27 to 14)
Abbreviations: HR rest, heart rate at rest; bpm, beats per minute; QT rest, QT interval at rest; HR walk, heart rate during walk; HR trot, heart rate dur-
ing trot; HR canter, heart rate during canter; HR gallop, heart rate during gallop; AFCL4CH, atrial fibrillation cycle length measured in the left atrial free
wall from the 4 chamber view; AFCLRA, atrial fibrillation cycle length from the right atrial dorsal wall at the level of the tuberculum intervenosum in a
right parasternal view; AFCLLLA, atrial fibrillation cycle length measured in the left atrial free wall from the left parasternal long-axis view.
Significant differences between groups are indicated by different superscripts (P< .05).
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The increased AFCL after sotalol treatment indicates slowing of
the atrial activation rate. During AF, the AFCL is somewhat longer than
the AERP because of the presence of a small excitable gap.19 The pro-
longation of AFCL after sotalol administration can be attributed to an
increase in the AERP or to widening of the temporal excitable gap. A
previous study in goats described a 24% increase of the AFCL during
IV sotalol infusion at 0.2 mg/kg/min.20 This mainly resulted from wid-
ening of the temporal excitable gap, while the AERP remained stable.
Sotalol administration in our study resulted in a modest increase of
AFCL by approximately 6%. In comparison, IV administration of the
class III antiarrhythmic drug amiodarone caused an AFCL increase up
to 100% in horses with naturally occurring chronic AF.21 In another
study, the class I drug flecainide administered IV to horses resulted in
an AFCL increase of approximately 35–50%.22,23 This is in line with the
experimental study in goats, where administration of flecainide caused
an AFCL increase of 48%.20 This was attributed to widening of the
temporal excitable gap, which results in decreased fragmentation of
wavelets and fusion of waves. This causes a reduction of the number
of wavelets in the atria and thus an increased chance of cardiover-
sion.22 Compared to amiodarone or flecainide, the effect of 2 mg/kg
sotalol PO q12h on AFCL was limited, and cardioversion of AF using
sotalol therapy alone seems unlikely in horses.
The limited effects of sotalol on AFCL can be explained by several
factors. First, the sotalol plasma concentrations were probably below
the therapeutic range described in human medicine. Plasma concentra-
tions were not measured in our study, but the steady state plasma con-
centration was 287 ng/mL in horses receiving 2 mg/kg body weight
sotalol PO twice daily for 9 days, while fed hay ad libitum during the
day.11 This is lower than the therapeutic plasma concentrations of
1000–3000 ng/mL described in human medicine.24 However, the sig-
nificant QT prolongation indicates class III activity despite the low
plasma concentrations. The limited effects on the AFCL also can be
explained by the reverse use dependence of the effect of sotalol on
atrial refractoriness, implying decreased class III effects at more rapid
atrial rates.25 Reverse use dependence of sotalol probably limits the
efficacy of sotalol against naturally occurring chronic AF with short
AFCL, compared to use-dependent drugs such as propafenone. Finally,
the effect of sotalol also might be affected by electrical remodeling of
the atrial myocardium. Decreased electrophysiological actions of class
III antiarrhythmic agents have been described in a goat model of
chronic AF, and was explained by decreased contribution of the rapid
delayed rectifier potassium current (IKr) to atrial repolarization in
remodeled myocardium.26
The AFCL measured in the left atrial free wall from the right para-
sternal 4-chamber view was shorter compared to the other views, as
has been described previously.17,18 The AFCL from this view did not
show a significant increase after sotalol administration. In the 4 cham-
ber view, the atrial myocardium is located at a large image depth and
more artifacts are present. This may explain the aberrant results from
this view. Another possible explanation is spatiotemporal organization
of AF, with high-frequency periodic sources, localized in the left atrium
or the pulmonary veins that maintain AF. This has been described in a
sheep model of induced AF.27 Based on this hypothesis, sotalol might
have little effect on AF sources in the left atrium, while it prolongs
AFCL in the RA by widening of the temporal excitable gap. The left
atrial wall visualized in the left parasternal view is closer to the
interatrial septum than the left atrial free wall from the 4-chamber
view, which may explain why the AFCL values were similar to those in
the RA.
Sotalol administration resulted in a significantly lower HR at rest
and during exercise. A 13–25% reduction in HR occurred after treat-
ment. Atrial fibrillatory rate decreased by 6%, but this was unlikely to
have contributed to a decrease in HR. Rather, the decreased HR likely
was caused by the nonselective b-blocking activity of sotalol. As a
competitive b-blocking agent, sotalol administration results in lower
intracellular Ca21 concentrations in the myocardial cells, causing a neg-
ative chronotropic effect by decreasing atrioventricular conduction.28
FIGURE 3 Heart rate at rest and during the exercise test (mean,
SD) in the sotalol group (A) and the control group (B). Significant
differences between the 2 examinations (before and after
treatment for the sotalol group) have been indicated by an asterisk
(P< .05)
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Sotalol could be a possible candidate drug for rate control therapy in
horses with AF in which cardioversion is not possible or declined by
the owner. Horses with AF often show no performance limitations dur-
ing low-level exercise but are deemed at increased risk to ride if the
average maximal HR during exercise, at an intensity that is at or slightly
exceeding the horse’s normal activities, exceeds 220/min, because high
HR during exercise has been associated with collapse.1 Long-term rate
control therapy possibly could decrease the HR during exercise in these
horses. Based on our study, it is unclear whether sotalol therapy could
permanently decrease the exercising HR in horses with AF and
whether riding a horse on sotalol is safe. First, the presence of QRS
complexes with an R-on-T morphology was not decreased after sotalol
treatment, and this might be associated with increased risk of ventricu-
lar fibrillation.14 Second, sotalol is not recommended for rate control
therapy in human medicine because of the risk of torsades de pointes
and sudden cardiac death associated with QT prolongation.29 The QT
prolongation in our study was limited to 9%, whereas in human medi-
cine an increase of 15%-20% is considered dangerous. Excessive QT
prolongation might occur in horses when sotalol therapy is combined
with other drugs, as has been described with general anesthesia.30
Third, the b-blocking activity of sotalol might result in a negative ino-
tropic effect and might affect blood pressure during exercise. However,
the negative inotropic effect is counteracted by the class III activity,
and no alterations of blood pressure have been described at rest in
horses receiving sotalol.11 Finally, sotalol cannot be used in horses dur-
ing competition, because it is listed in the Federation Equestre Interna-
tionale prohibited substances database as a controlled medication.
In human medicine, sotalol is used to maintain sinus rhythm after
cardioversion of AF, although proarrhythmogenic effects and a small
increase in all-cause mortality have been associated with its use.31 Our
study did not evaluate whether sotalol decreases the risk of AF recur-
rence, because doing so would require a long-term follow-up study in
which horses are randomly treated with sotalol or placebo after
cardioversion.32
The main limitation of our study is that sotalol was not adminis-
tered in a double-blinded fashion with random assignment of horses to
either the treatment group or the control group. Instead, all horses
admitted for AF treatment in the timespan of 1 year were administered
sotalol before TVEC as part of the standard treatment protocol. The
control group consisted of horses consecutively admitted for AF treat-
ment in a different calendar year, during which sotalol administration
was not part of the treatment protocol because of safety concerns
when combined with general anesthesia or administration of amioda-
rone in case of early recurrence of AF. The same study protocol was
followed. Therefore, no difference between the 2 groups was
expected.
In conclusion, sotalol administration results in class III antiarrhyth-
mic effects and b-blocking activity in horses with AF. Therefore, sotalol
shows potential as a rate control drug in exercising horses with AF.
However, the safety of sotalol administration needs further evaluation
because the HR reduction after sotalol therapy was limited, the risk of
R-on-T phenomenon was not decreased and the proarrhythmic effects
during exercise are not known.
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